| Intravenous golimumab is a highly effective anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis patients switching directly from infliximab. |
| This manuscript provides real-world evidence that rheumatoid arthritis patients switching from infliximab to intravenous golimumab have improved clinical outcomes. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.